Profile
LIPO VRTX REGN SGEN ALNY ARGX
Company Name Lipella Pharmaceuticals Inc. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. Alnylam Pharmaceuticals, Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $10.54M $116.96B $55.30B $43.15B $41.50B $33.66B
Employees 0.01K 6.10K 15.16K 3.26K 2.23K 1.60K
CEO Dr. Jonathan Kaufman M.B.A., Ph.D. Dr. Reshma Kewalramani FASN, M.D. Leonard S. Schleifer David R. Epstein Yvonne L. Greenstreet Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
Ratings
LIPO VRTX REGN SGEN ALNY ARGX
Quant Rating Score 2 2 4 3 1 1
Quant Rating Sell Sell Buy Neutral Strong Sell Strong Sell
Trading
LIPO VRTX REGN SGEN ALNY ARGX
Last Close $0.8676 $445.2 $525 $228.74 $326.09 $551.22
High 52 $4.65 $516.74 $1201.76 $228.74 $326.09 $671.75
Low 52 $0.31 $396.64 $482.92 $228.74 $224.58 $434.22
Price vs. 52 Week High -81.34 % -13.84 % -56.31 % 0 % 0 % -17.94 %
Price vs. 52 Week Low 179.87 % 12.24 % 8.71 % 0 % 45.2 % 26.94 %
Total Return
LIPO VRTX REGN SGEN ALNY ARGX
1 Month Return -68.79 % 0.71 % 7.08 % 0 % 7.07 % -3.84 %
3 Month Return -66.24 % -8.16 % -14.91 % 0 % 27.4 % -2.78 %
6 Month Return -71.55 % 10.55 % -26.3 % 0 % 38.58 % -10.37 %
9 Month Return 96.73 % -5.23 % -49.85 % 0 % 18.12 % 0.72 %
YTD Return -71.55 % 10.55 % -26.3 % 0 % 38.58 % -10.37 %
1 Year Return 92.8 % -5.53 % -50.33 % 0 % 34.02 % 26.94 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
LIPO VRTX REGN SGEN ALNY ARGX
Dividend Yield Percentage (TTM) - - 0.34 % - - -
Dividend Paid and Capex Coverage Ration (TTM) - -3.53 % 3.85 % -5.87 % -1.49 % -44.32 %
Dividend Per Share (TTM) - - 1.76 % - - -
Payout Ratio (TTM) - - 2.08 % - - -
Growth
LIPO VRTX REGN SGEN ALNY ARGX
Asset Growth -25.25 % -0.87 % 36.55 %
Gross Profit Growth -18.83 % 10.25 % 77.08 %
Revenue Growth 19.29 % 11.66 % 78.6 %
Revenue 3 Year 41.66 % 45.6 % 275.84 %
Revenue 5 Year -80.85 % 163.93 % 1701.04 %
Revenue 10 Year -80.85 % 1632.15 % 5950.81 %
EBIT Growth -8.86 % -93.69 % 128.87 %
Net Income Growth -8.6 % -114.8 % 382.34 %
Net Income 3 Yeari Growth Per Share -84.19 % -122.89 % 274.39 %
Net Income 5 Yeari Growth Per Share -1911.83 % -145.38 % 396.61 %
Net Income 10 Yeari Growth Per Share -1911.83 % 33.84 % 938.02 %
Operating Income Growth -7.05 % -106.08 % 94.91 %
Operating Cash Flow Growth (CFG) -25.41 % -113.93 % 80.31 %
Operating 3 Year CFG -173.56 % -118.65 % 88.36 %
Operating 5 Year CFG -2405.25 % -131.3 % -135.21 %
Operating 10 Year CFG -2405.25 % 12.43 % -64 %
EPS Growth 22.24 % -114.8 % 369.77 %
EPS Diluted Growth 22.24 % -114.97 % 347.67 %
Book Value Per Share -56.33 % -6.59 % 28.16 %
Share Holder 3 Year Equity Growth Per Share -7.64 % 62.6 % 85.14 %
Share Holder 5 Year Equity Growth Per Share 502.32 % 168.85 % 200.53 %
Share Holder 10 Year Equity Growth Per Share 502.32 % 1265.7 % 1039.11 %
Dividend Per Share Growth - - -
Dividend 3 Year Growth Per Share - - -
Dividend 5 Year Growth Per Share - - -
Dividend 10 Year Growth Per Share - - -
Debt Growth -65.15 % 116.42 % 95.27 %
Free Cash Flow Growth -24.84 % -124.1 % 67.46 %
Updated On 31 Dec 2024 31 Dec 2024 31 Dec 2024
Profitability
LIPO VRTX REGN SGEN ALNY ARGX
Gross Profit Margin TTM 97.76 % 86.03 % 84.94 % 79.1 % 86.01 % 46.33 %
Return on Assets TTM -26.98 % -4.32 % 11.98 % -16.61 % -6.4 % 13.45 %
Return on Equity TTM -128.33 % -6.25 % 14.77 % -20.8 % -509.33 % 16.83 %
Return on Capital Employed TTM -32.65 % -3.89 % 11.35 % -21.46 % -3.68 % -0.5 %
Net Income Per EBT TTM 100 % 329.41 % 90.27 % 101.33 % 75.89 % 25990.14 %
EBT Per Ebit TTM 98.4 % 40.44 % 129.3 % 98.26 % 308.03 % -11.64 %
EBIT Per Revenue TTM -1026.1 % -6.69 % 27.37 % -31.24 % -4.91 % -1.24 %
Cash Flow To Debt Ratio TTM -5953.61 % -59.44 % 146.15 % -1043.73 % -3.47 % -201.37 %
Receivables Turnover TTM - 6.15 2.53 3.91 5.62 2.36
Payables Turnover TTM - 3.49 3.01 1.97 3.37 2.39
Inventory Turnover TTM - 1.14 0.66 0.96 5.01 2.93
Fixed Asset Turnover TTM 550.57 % 421.34 % 300.07 % 665.41 % 337.41 % 5106.8 %
Asset Turnover TTM 2.67 % 48.51 % 37.52 % 53.41 % 55.72 % 35.83 %
Operating Cash Flow Per Share TTM -694.62 -3.82 37.05 -2.46 -0.35 -1.07
Free Cash Flow Per Share TTM -694.62 -4.9 28.3 -2.88 -0.58 -1.09
Cash Per Share TTM 205416.36 % 2413.86 % 7825.12 % 939.52 % 2024.29 % 4688.94 %
Operating Cash Flow Sales Ratio TTM -1100.85 % -8.83 % 28.06 % -23.12 % -1.92 % -3.54 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 128.33 % 76.4 % 117.04 % 167.11 % 102.26 %
Cash Flow Coverage Ratios TTM -5953.61 % -59.44 % 146.15 % -1043.73 % -3.47 % -201.37 %
Price To Free Cash Flows Ratio TTM -0.01 -92.97 18.31 -81.26 -550.45 -433.65
Price To Operating Cash Flows Ratio TTM - -119.36 14.06 -93.1 -914.84 -515.25
Price Cash Flow Ratio TTM - -119.36 14.06 -93.1 -914.84 -515.25
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 39.375
AARD Aardvark Therapeutics, Inc. Common Stock 13.52
ABCL AbCellera Biologics Inc. 3.43
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.68
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.16
ABPWW 0.0207
ABSI Absci Corporation 2.57
ABUS Arbutus Biopharma Corporation 3.09
ABVC ABVC BioPharma, Inc. 2.225
ABVX Abivax SA American Depositary Shares 7.65
ACAD ACADIA Pharmaceuticals Inc. 21.57
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.61
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 2.26
ACIU AC Immune SA 2.03
ETFs With Exposure to LIPO
Ticker ETF Name Weight Percentage Price
VXF Vanguard Extended Market Index Fund 0 192.71
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 146.26
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 146.27
VEMPX Vanguard Extended Market Index InstlPlus 0 360.93
Unlock